In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Mylan Labs to acquire King Pharmaceuticals; deal cancelled

Executive Summary

Mylan Laboratories Inc. has agreed to acquire King Pharmaceuticals for about $4.2bn. Under terms of the stock swap, King shareholders receive 0.9 Mylan common shares for each King common held. Based on Mylan's average share price prior to announcement, it paid $17.33 per King share, a 65% premium to market.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Withdrawn
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Stock

Related Companies

Advertisement
UsernamePublicRestriction

Register